Sickle Cell Gene Therapy May Need New US-Backed Payment Program, Grogan Suggests
Executive Summary
Former senior advisor to President Trump warns that failure to reform drug pricing practices has seriously handicapped prospects for reimbursing cell and gene therapy under existing US payer programs.
You may also be interested in...
Cell And Gene Therapy Outcomes-Based Contracts In Medicaid Need ‘National’ Support,' HHS Says
The demonstration project planned by the US Centers for Medicare and Medicaid Services is in keeping with past agency efforts to promote value-based contracts for cell and gene therapy.
Reality Check? Medicaid Costs From Cell, Gene Therapies Projected At (Just) $1Bn-$4Bn By 2030
Based on the current pipeline of durable therapies, MIT research indicates ‘it’s not a big lift to cover the children and the adults in Medicaid for these products,’ Mark Trusheim says.
Drug Pricing Reform In Medicaid: Watch This Space
Some manufacturers may have to start essentially paying Medicaid programs to cover their drugs beginning in 2024 under a provision in the US economic relief bill headed to President Biden.